3D remodelled DNA helix structure
About us We want to help people do more, feel better, live longer.
Today there are still millions of people without access to basic healthcare, thousands of diseases without adequate treatments and millions more people who suffer from everyday ailments. At GSK we want to change this.
Read morePress releases
- Phase II study results showed comparable viral suppression rates at 96 weeks for a two-drug regimen of long-acting cabotegravir and rilpivirine and a three-drug regimen in patients with HIV
- GSK submits US regulatory filing of Arnuity Ellipta in children with asthma
- GSK announces Board and Committee changes
Tweets from GSK
-
GSK @GSK
ICYMI: We’re delighted to welcome leading scientist & physician Dr Laurie Glimcher to our Board. Read more:… twitter.com/i/web/status/8…
about 2 hours ago -
GSK @GSK
Can you imagine a scientific discovery filling a basketball stadium? Marty's #HIV research did exactly that!… twitter.com/i/web/status/8…
about 3 days ago -
GSK @GSK
#FlashbackFriday to 30 years ago when Marty St. Clair discovered she’d made a scientific breakthrough in #HIV resea… twitter.com/i/web/status/8…
about 3 days ago
